Pfizer Inc. (NYSE:PFE) Shares Purchased by Nexus Investment Management ULC

Nexus Investment Management ULC raised its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 1.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 818,287 shares of the biopharmaceutical company's stock after acquiring an additional 13,475 shares during the period. Pfizer makes up about 2.2% of Nexus Investment Management ULC's investment portfolio, making the stock its 24th largest position. Nexus Investment Management ULC's holdings in Pfizer were worth $21,709,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter worth approximately $26,000. Gladius Capital Management LP increased its stake in shares of Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 38,015 shares during the period. Quarry LP bought a new stake in shares of Pfizer in the second quarter valued at about $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Pfizer in the third quarter worth about $35,000. Finally, Joseph Group Capital Management increased its position in Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 771 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.06% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on PFE shares. UBS Group cut their price target on Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Citigroup initiated coverage on shares of Pfizer in a research report on Friday, October 25th. They issued a "neutral" rating and a $30.00 price objective on the stock. Cantor Fitzgerald reissued an "overweight" rating and set a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Wolfe Research initiated coverage on Pfizer in a research report on Friday, November 15th. They set an "underperform" rating and a $25.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of "Moderate Buy" and a consensus target price of $32.00.

Pfizer Price Performance

NYSE PFE traded down $0.19 during mid-day trading on Friday, hitting $26.30. The stock had a trading volume of 35,146,711 shares, compared to its average volume of 35,869,448. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market capitalization of $149.06 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 0.64 and a beta of 0.64. The firm's 50 day moving average is $26.08 and its 200 day moving average is $27.99. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer's quarterly revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.17) earnings per share. Equities research analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.54%. This is a positive change from Pfizer's previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer's dividend payout ratio is presently 232.43%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.